Anxious Depression

The short version

●Anxious depression is a major depressive episode with prominent anxiety — restlessness, tension, worry, fear that something awful may happen — captured in DSM-5 as the "anxious distress" specifier.
●It is common and tends to be more severe, slower to respond to standard antidepressants, and associated with higher suicide risk than non-anxious depression.
●First-line treatment is still an antidepressant (often an SSRI/SNRI) plus therapy, but response rates to standard medication are lower, so it more often becomes treatment-resistant.
●Intravenous ketamine works about as well in anxious depression as in non-anxious depression — the anxiety does not blunt its antidepressant effect.¹
●This matters because anxious depression is exactly the harder-to-treat group where a different mechanism can help when SSRIs disappoint.²
●Tovani treats anxious depression; the calm, supported set-and-setting of dosing is designed with anxious patients in mind.

Clinical definition

Anxious depression refers to a major depressive episode accompanied by prominent anxiety symptoms. DSM-5 formalizes this as the "with anxious distress" specifier, requiring at least two of: feeling keyed up or tense, unusually restless, difficulty concentrating because of worry, fear that something awful may happen, and fear of losing control. It can be conceptualized either categorically (the specifier) or dimensionally (high anxiety symptom burden within depression). Clinically it matters because it predicts greater severity, longer episodes, poorer and slower response to first-line antidepressants, and elevated suicide risk — making it one of the more common routes into treatment-resistant depression.

How it differs from related conditions

vs. Generalized anxiety disorder

In GAD, chronic worry is the primary disorder; in anxious depression, anxiety rides on top of a depressive episode that is the core problem. The two frequently co-occur.

vs. Major depressive disorder

Anxious depression is MDD with the anxious-distress specifier — a subtype, not a separate illness — but one that behaves differently in treatment.

vs. Treatment-resistant depression

Because anxious depression responds less well to first-line antidepressants, it disproportionately becomes treatment-resistant, where ketamine is considered.

First-line treatments

SSRIs / SNRIs

Still first-line, though response is often slower and less complete than in non-anxious depression; adequate dose and duration matter.

Psychotherapy (CBT)

Cognitive-behavioral therapy targets both the depressive and anxious cognitions and is effective alongside medication.

Avoiding long-term benzodiazepines

Benzodiazepines may calm acute anxiety but carry dependence risk and don't treat the depression; used sparingly if at all.

Augmentation when partial

Adding an atypical antipsychotic or switching class is common when an SSRI helps the mood but anxiety persists.

When standard treatments fail

Because anxious depression responds less reliably to first-line antidepressants, many patients arrive at the treatment-resistant stage after two adequate trials. At that point the options are augmentation, switching mechanism, and rapid-acting glutamatergic treatment — ketamine or esketamine — which trials show works about as well whether or not the depression is anxious.

Where ketamine fits

A common worry is that high anxiety might blunt ketamine's benefit, or that the dissociative experience could be intolerable for anxious patients. The data are reassuring on the first point: in a dedicated analysis, intravenous ketamine improved depression about equally in anxious and non-anxious treatment-resistant patients.¹ Combined with ketamine's established efficacy in treatment-resistant depression generally,² this makes it a sensible option precisely for the anxious group that first-line antidepressants most often fail. The experience itself is managed with preparation and a calm, supported setting so anxious patients know what to expect.

Where this fits with Tovani

Tovani treats anxious depression. For patients whose worry makes the idea of a dissociative experience daunting, preparation and the set-and-setting of dosing are designed to feel contained and predictable — you'll know what the experience involves before you begin, with support throughout. The goal is the antidepressant benefit, which research shows the anxiety does not take away.

Check eligibility Find treatment options The science behind ketamine

Frequently asked

Will ketamine work if my depression comes with a lot of anxiety?

Likely yes. A study designed to answer exactly this found ketamine improved depression about equally in anxious and non-anxious patients — the anxiety didn't reduce the benefit. Anxious depression is actually a group where first-line antidepressants often disappoint, so a different mechanism can be especially useful.

I'm anxious — won't the dissociation make it worse?

That's a common worry. The dissociative experience is temporary and managed with preparation and a calm, supported setting so you know what to expect before you begin. Most anxious patients tolerate it well, and the lasting effect is on mood, not anxiety in the moment.

Is anxious depression different from having both depression and an anxiety disorder?

Somewhat. Anxious depression is a depressive episode with prominent anxiety symptoms (the "anxious distress" specifier). You can also have a separate anxiety disorder like GAD at the same time. Either way, the depression is the core target.

Why is anxious depression harder to treat?

It tends to be more severe, last longer, and respond more slowly and less completely to standard antidepressants, with higher suicide risk. That's why it more often becomes treatment-resistant and why rapid-acting options matter.

References

Salloum NC et al. 2019, Depression & Anxiety — IV ketamine improved treatment-resistant depression similarly in anxious and non-anxious patients. (PMID 30597688)
Fava M et al. 2020, Molecular Psychiatry — Double-blind, placebo-controlled dose-ranging trial establishing IV ketamine's efficacy in treatment-resistant depression. (PMID 30283029)

Last reviewed by Dr. Ben Soffer, DO on June 2, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.